Laia Rosich

1.1k total citations
21 papers, 721 citations indexed

About

Laia Rosich is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Laia Rosich has authored 21 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 10 papers in Molecular Biology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Laia Rosich's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Ubiquitin and proteasome pathways (5 papers). Laia Rosich is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Ubiquitin and proteasome pathways (5 papers). Laia Rosich collaborates with scholars based in Spain, Germany and United States. Laia Rosich's co-authors include Fèlix Bosch, Dolors Colomer, Elı́as Campo, Mònica López‐Guerra, Gaël Roué, Sílvia Xargay‐Torrent, Patricia Pérez‐Galán, Ifigènia Saborit-Villarroya, Arnau Montraveta and Neus Villamor and has published in prestigious journals such as Blood, Oncogene and Scientific Reports.

In The Last Decade

Laia Rosich

21 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laia Rosich Spain 15 410 162 151 134 121 21 721
Gábor Barna Hungary 15 387 0.9× 119 0.7× 92 0.6× 173 1.3× 153 1.3× 64 711
Mercè de Frías Spain 13 511 1.2× 184 1.1× 94 0.6× 237 1.8× 103 0.9× 17 734
Vicente Fresquet Spain 16 442 1.1× 154 1.0× 132 0.9× 166 1.2× 105 0.9× 24 703
Andrey Sudarikov Russia 12 286 0.7× 157 1.0× 136 0.9× 88 0.7× 130 1.1× 131 611
Matthew J. Saabye United States 8 267 0.7× 85 0.5× 56 0.4× 190 1.4× 159 1.3× 8 703
Barbara Cebula‐Obrzut Poland 21 527 1.3× 342 2.1× 218 1.4× 304 2.3× 309 2.6× 74 1.1k
Natalie Grinshtein Canada 16 359 0.9× 82 0.5× 58 0.4× 284 2.1× 250 2.1× 23 850
Nicholas P. D. Liau Australia 9 353 0.9× 84 0.5× 77 0.5× 370 2.8× 281 2.3× 14 781
Weiming Duan China 16 406 1.0× 93 0.6× 52 0.3× 328 2.4× 146 1.2× 39 819
Rajinder Singh India 8 182 0.4× 66 0.4× 77 0.5× 199 1.5× 374 3.1× 21 723

Countries citing papers authored by Laia Rosich

Since Specialization
Citations

This map shows the geographic impact of Laia Rosich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laia Rosich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laia Rosich more than expected).

Fields of papers citing papers by Laia Rosich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laia Rosich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laia Rosich. The network helps show where Laia Rosich may publish in the future.

Co-authorship network of co-authors of Laia Rosich

This figure shows the co-authorship network connecting the top 25 collaborators of Laia Rosich. A scholar is included among the top collaborators of Laia Rosich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laia Rosich. Laia Rosich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosich, Laia, Mònica López‐Guerra, Irene López‐Oreja, et al.. (2020). Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Scientific Reports. 10(1). 22153–22153. 24 indexed citations
2.
Schulz, Ralph, Morihiro Higashi, Marta Aymerich, et al.. (2019). Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia. 34(1). 100–114. 38 indexed citations
3.
López‐Guerra, Mònica, Sílvia Xargay‐Torrent, Patricia Fuentes, et al.. (2019). Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. Oncogene. 39(6). 1185–1197. 27 indexed citations
4.
Rosich, Laia, Ralph Schulz, Morihiro Higashi, et al.. (2018). Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 2650–2650. 1 indexed citations
5.
Hanna, Bola S., Vanina Rodríguez, Laia Rosich, et al.. (2018). Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. International Journal of Cancer. 144(11). 2762–2773. 8 indexed citations
6.
Higashi, Morihiro, et al.. (2017). New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. Expert Opinion on Drug Discovery. 12(10). 1041–1052. 4 indexed citations
7.
Montraveta, Arnau, Sílvia Xargay‐Torrent, Laia Rosich, et al.. (2015). Bcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget. 6(25). 21159–21172. 10 indexed citations
8.
Xargay‐Torrent, Sílvia, Mònica López‐Guerra, Laia Rosich, et al.. (2015). The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget. 6(26). 22734–22749. 58 indexed citations
9.
Montraveta, Arnau, Sandra Columba‐Cabezas, Guillem Clot, et al.. (2015). CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget. 7(5). 5507–5520. 17 indexed citations
10.
Matas‐Céspedes, Alba, Vanina Rodríguez, Susana G. Kalko, et al.. (2014). Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). Clinical Cancer Research. 20(13). 3458–3471. 21 indexed citations
11.
López‐Guerra, Mònica, Sílvia Xargay‐Torrent, Laia Rosich, et al.. (2014). The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 29(1). 96–106. 55 indexed citations
12.
Montraveta, Arnau, Sílvia Xargay‐Torrent, Mònica López‐Guerra, et al.. (2014). Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget. 5(3). 726–739. 16 indexed citations
13.
Rosich, Laia, Arnau Montraveta, Sílvia Xargay‐Torrent, et al.. (2014). Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget. 5(16). 6788–6800. 31 indexed citations
14.
Rosich, Laia, Sílvia Xargay‐Torrent, Mònica López‐Guerra, et al.. (2012). Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma. Clinical Cancer Research. 18(19). 5278–5289. 57 indexed citations
15.
Rosich, Laia, Dolors Colomer, & Gaël Roué. (2012). Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. Autophagy. 9(1). 115–117. 22 indexed citations
16.
Xargay‐Torrent, Sílvia, Mònica López‐Guerra, Ifigènia Saborit-Villarroya, et al.. (2012). The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. Blood. 120(21). 1647–1647. 1 indexed citations
17.
Xargay‐Torrent, Sílvia, Mònica López‐Guerra, Arnau Montraveta, et al.. (2012). Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma. Clinical Cancer Research. 19(3). 586–597. 23 indexed citations
18.
Rosich, Laia, Sílvia Xargay‐Torrent, Mònica López‐Guerra, et al.. (2011). Abstract C72: Counteracting autophagy allows to overcome resistance to the mTOR everolimus in mantle cell lymphoma.. Molecular Cancer Therapeutics. 10(11_Supplement). C72–C72. 1 indexed citations
19.
Roué, Gaël, Patricia Pérez‐Galán, Anna Mozos, et al.. (2010). The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood. 117(4). 1270–1279. 87 indexed citations
20.
Bosch, Fèlix & Laia Rosich. (2008). The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel Prize. Pharmacology. 82(3). 171–179. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gábor Barna Breakdown of academic impact, for papers by Mercè de Frías Breakdown of academic impact, for papers by Vicente Fresquet Breakdown of academic impact, for papers by Andrey Sudarikov Breakdown of academic impact, for papers by Matthew J. Saabye Breakdown of academic impact, for papers by Barbara Cebula‐Obrzut Breakdown of academic impact, for papers by Natalie Grinshtein Breakdown of academic impact, for papers by Nicholas P. D. Liau Breakdown of academic impact, for papers by Weiming Duan Breakdown of academic impact, for papers by Rajinder Singh
Rankless by CCL
2026